Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 3/20 | 0.49 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MET | P08581 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2586124 | 0.85 | OPRM1 (0.47) | ADAM17KDM1A | |
| SCHEMBL2589090 | 0.82 | LMNA (0.56) | USP2MAPTMAPK1KMT2AESR2 | |
| Hydrochloric Acid SCHEMBL2581811 | 0.82 | LMNA (0.55) | USP2MAPTMAPK1KMT2AESR2 | |
| Hydrochloric Acid SCHEMBL2587759 | 0.81 | HTT (0.54) | KMT2A | |
| SCHEMBL2583630 | 0.81 | ADAM17 (0.46) | ADAM17 | |
| SCHEMBL2589017 | 0.79 | S1PR5 (0.39) | ADAM17S1PR5ALDH1A1 | |
| Hydrochloric Acid SCHEMBL2582753 | 0.78 | OPRL1 (0.49) | S1PR5 | |
| SCHEMBL2588316 | 0.76 | KDM1A (0.46) | KDM1AALDH1A1 | |
| Hydrochloric Acid SCHEMBL2584425 | 0.75 | KDM1A (0.46) | KDM1AALDH1A1 | |
| SCHEMBL12041582 | 0.73 | MAPT (0.69) | EGFRUSP2MAPTMAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859777-B2 | 4-fluoro-4-arylpiperdin-1-yl derivatives as mu opioid function moderators | KINENTIA BIOSCIENCES LLC (US) | 2014-10-14 | — | — | US | disclosed |
| US-20130045165-A1 | 4-FLUORO-4-ARYLPIPERDIN-1-YL DERIVATIVES AS MU OPIOID FUNCTION MODERATORS | KINENTIA BIOSCIENCES, LLC (US) | 2013-02-21 | — | — | US | disclosed |
| WO-2011137331-A2 | 4-FLUORO-4-ARYLPIPERDIN-1-YL DERIVATIVES AS MU OPIOID FUNCTION MODERATORS | KINENTIA BIOSCIENCES LLC (US) | 2011-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045165-A1 | 4-FLUORO-4-ARYLPIPERDIN-1-YL DERIVATIVES AS MU OPIOID FUNCTION MODERATORS | OPRD1, OPRK1, OPRM1 | ADAM17 4036/4885S1PR5 2302/4885KDM1A 2818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.